Browse the latest research summaries in the field of regenerative medicine for spinal cord injury patients and caregivers.
Showing 1,331-1,340 of 2,298 results
Journal of Nanobiotechnology, 2024 • May 31, 2024
This study introduces a novel antioxidant strategy for SCI treatment using ZIF-8 encapsulated selenium nanoparticles (SeNPs@ZIF-8) coated with ferrostatin-1 (FSZ NPs). The FSZ NPs demonstrate synergis...
KEY FINDING: SeNPs@ZIF-8 nanoparticles, particularly medium-sized ones (SSe@ZIF-8), exhibit enhanced ROS scavenging ability compared to SeNPs alone, reducing cytotoxicity.
Cell Death Discovery, 2024 • April 24, 2024
This study investigates the therapeutic potential of salidroside in treating spinal cord injury (SCI). The research focuses on salidroside's impact on nerve regeneration, glial scar formation, astrocy...
KEY FINDING: Salidroside enhances functional recovery in SCI mice by promoting axonal regeneration, myelin reconstitution, and inhibiting glial scar formation and the activation of neurotoxic A1 astrocytes.
International Journal of Nanomedicine, 2024 • May 8, 2024
This study introduces an innovative approach to treating spinal cord injury (SCI) by using an injectable hydrogel (FTY720-CDs@GelMA) loaded with carbon dots (CDs) and FTY720, combined with neural stem...
KEY FINDING: The FTY720-CDs@GelMA hydrogel significantly enhanced NSC proliferation while promoting neuronal regeneration and synaptic formation, thereby reducing cavity area in the injured spinal cord.
Age and Ageing, 2024 • January 31, 2024
This study investigated the interaction between dietary/nutritional factors and neurogenesis-centred biological susceptibility on cognitive decline (CD), dementia, and depressive symptomatology. The r...
KEY FINDING: Increased plasma lycopene concentrations, higher red meat consumption, and lower poultry consumption were associated with an increased risk for Alzheimer’s disease in individuals with a neurogenesis-centred susceptibility.
Stem Cell Research & Therapy, 2024 • May 9, 2024
This study investigates the therapeutic potential of human umbilical cord mesenchymal stem cell-derived exosomes (HucMSC-EX) loaded into Gelfoam for treating spinal cord injury (SCI) in rats. The resu...
KEY FINDING: Exosome treatment consistently increased the BBB score from 1 to 8 weeks compared with the Gelfoam-saline and SCI control groups, indicating improved locomotor function.
Stem Cell Research & Therapy, 2024 • May 7, 2024
This study aimed to evaluate potential synergistic effects of hUC-MSC-sEVs with rhBMP-2 in promoting regeneration of a metaphyseal femoral defect in an osteoporotic rat model. The results demonstrated...
KEY FINDING: The co-application of hUC-MSC-sEVs can improve the efficacy of rhBMP-2 to promote the regeneration of osteoporotic bone defects.
Genome Research, 2019 • March 1, 2019
This study presents a cost-effective approach to scaffolding the large axolotl genome and validates the resulting assembly using FISH and analysis of synteny conservation across vertebrates. The utili...
KEY FINDING: The study successfully assembled the axolotl genome into 14 chromosomes, covering 27.3 Gb and encompassing 94% of annotated gene models.
International Journal of Nanomedicine, 2024 • May 13, 2024
This study investigates the effects of MgAl-LDH nanoparticles of varying sizes on the differentiation of mouse embryonic stem cells (mESCs) into neural progenitor cells (NPCs). The results demonstrate...
KEY FINDING: MgAl-LDH nanoparticles of 100 nm size significantly promote the differentiation of ESCs into NPCs compared to 30 nm and 50 nm sizes.
J Venom Anim Toxins incl Trop Dis, 2024 • May 20, 2024
This study investigated the effects of local mp-HNK-1 and systemic UA treatments following ventral root avulsion and reimplantation in mice. UA treatment showed long-term neuroprotection, reduced glia...
KEY FINDING: UA treatment led to long-term neuroprotection, decreasing microglial reactions and reactive astrogliosis.
Bioactive Materials, 2024 • May 7, 2024
This study introduces a novel therapeutic approach for spinal cord injury (SCI) that combines ROS-responsive nanoparticles, a ferroptosis inhibitor prodrug (Feb-1), and mesenchymal stem cells (MSCs). ...
KEY FINDING: The ROS-responsive nanoparticles (ROS Nano@Feb-1) were successfully constructed and can release the drug Feb-1 in response to high ROS levels, which are characteristic of SCI.